Holen Sie sich die Stockscreener-App
5.19
3.35%
-0.18
Schlusskurs vom Vortag:
$5.37
Offen:
$5.49
24-Stunden-Volumen:
167.72K
Relative Volume:
0.87
Marktkapitalisierung:
$105.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.63M
KGV:
-2.7139
EPS:
-1.9124
Netto-Cashflow:
$-47.63M
1W Leistung:
-0.57%
1M Leistung:
-2.08%
6M Leistung:
+18.22%
1J Leistung:
+50.00%
1-Tages-Spanne:
$5.06
$5.55
1-Wochen-Bereich:
$5.06
$5.55
52-Wochen-Spanne:
$3.06
$5.73
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
5.19 | 106.03M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid receives EMA validation for D-PLEX100 application - Investing.com
PolyPid’s D-PLEX₁₀₀ Application Validated by EMA, Advancing Dual EU–U.S. Reviews - TipRanks
PolyPid receives EMA validation for D-PLEX100 application By Investing.com - Investing.com Canada
PolyPid regains European rights for D-PLEX after deal ends By Investing.com - Investing.com Canada
PolyPid Reclaims European Rights to D-PLEX₁₀₀ After Ending Advanz Pharma Deal - TipRanks
A drug designed to release antibiotics for 30 days clears an EU review step at PolyPid (PYPD). - Stock Titan
A treatment designed to prevent infections after abdominal surgery enters European review - Stock Titan
A European licensing deal ends by mutual agreement between PolyPid (PYPD) and ADVANZ PHARMA. - Stock Titan
PolyPid Announces Termination of ADVANZ PHARMA Europe Agreement for D-PLEX100, Regains European Rights - Quiver Quantitative
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities - Yahoo Finance
PolyPid at Lytham Partners: FDA decision nears for lead drug - Investing.com India
Polypid Stock Price Forecast. Should You Buy PYPD? - StockInvest.us
PolyPid stock gains after fresh data as investors watch cash runway - AD HOC NEWS
PolyPid Ltd.Ordinary Shares (Nasdaq:PYPD) Stock Quote - The Chronicle-Journal
PolyPid Announces Participation in Upcoming Fall Investor Conferences - globenewswire.com
PYPD Q2 2026 Earnings: PolyPid Posts Narrower-Than-Expected Loss With No Reported RevenueFinancial Data - dars.gov.et
PolyPid (PYPD): Will The November FDA Decision Propel The Stock? - RTTNews
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - vinanet.vn
PolyPid (PYPD) Q2 2026 Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Closing Reaction: Shares Close 1.40% Higher in Latest TradingRetail Earnings Report - vinanet.vn
PolyPid | 3: Initial statement of beneficial ownership of securities- Warshavsky Ori - Moomoo
PolyPid | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD - MarketBeat
PolyPid Ltd (PYPD) Stock News Today - TradingKey
PolyPid Ltd. (PYPD) Holds Near $4.75 as Clinical-Stage Biotech Navigates Key Support ZoneCall Resistance - vinanet.vn
Conferencia de resultados del 2T de 2026 de PolyPid (PYPD): revisión prioritaria de D-PLEX100 y acuerdo con Azurity - TradingKey
What is HC Wainwright's Forecast for PolyPid Q3 Earnings? - MarketBeat
PolyPid (PYPD) Earnings Call zum 2. Quartal 2026: Prioritäre Prüfung für D-PLEX100 und Azurity-Deal - TradingKey
PolyPid Ltd (PYPD) Earnings Date & Reports & Earnings News - TradingKey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure - Stock Titan
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneBollinger Walk - dars.gov.et
HC Wainwright Issues Negative Estimate for PolyPid Earnings - MarketBeat
PolyPid Earnings Call: Priority Review, Big Azurity Deal - TipRanks
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance
PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline - TipRanks
PolyPid Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk - Stock Titan
Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99% - Stock Titan
PolyPid Releases Q2 2026 Financial Results - AlphaStreet
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
PolyPid Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA - scanx.trade
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Australia
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
PolyPid Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 - marketscreener.com
PolyPid Wins FDA Priority Review for D-PLEX₁₀₀ and Locks In $30 Million Azurity Milestones - TipRanks
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028 - tradingview.com
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
PolyPid (PYPD) secures D-PLEX100 FDA priority review and $30M Azurity deal - Stock Titan
Press Release: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Moomoo
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):